Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Amyloidosis cancers with)
6,495 results
  • Zinc-Epigallocatechin-3-gallate Network-Coated Nanocomposites against the Pathogenesis of Amyloid-Beta. [Journal Article]
    ACS Appl Mater Interfaces. 2023 Feb 01 [Online ahead of print]Andrikopoulos N, Li Y, … Ke PC
  • The aggregation of amyloid beta (Aβ) is a hallmark of Alzheimer's disease (AD), a major cause of dementia and an unmet challenge in modern medicine. In this study, we constructed a biocompatible metal-phenolic network (MPN) comprising a polyphenol epigallocatechin gallate (EGCG) scaffold coordinated by physiological Zn(II). Upon adsorption onto gold nanoparticles, the MPN@AuNP nanoconstruct elici…
  • Advancements and future trends of immunotherapy in light-chain amyloidosis. [Review]
    Crit Rev Oncol Hematol. 2023 Jan 22 [Online ahead of print]Mahadevia H, Ponvilawan B, … Raza S
  • Light-chain (AL) amyloidosis is a type of plasma cell neoplasm with abnormal monoclonal immunoglobulin light-chain production and their subsequent deposition in tissues causing end-organ damage. In addition to existing treatments including autologous stem cell transplantation, there is a need for other approaches for eradicating abnormal plasma cells and amyloid tissue deposits. Treatment strateg…
  • Hemodynamic Profiling and Prognosis in Cardiac Amyloidosis. [Journal Article]
    Circ Heart Fail. 2023 Jan 25 [Online ahead of print]Martens P, Bhattacharya S, … Tang WHW
  • CONCLUSIONS: Hemodynamic variables are grossly abnormal in CA, but elevated filling pressures are prognostic at significantly higher threshold values than classic cutoff values. CI is the hemodynamic variable most strongly associated with outcome and functionality in CA.
  • Conjunctival Amyloidosis: A Report of Two Cases with Review of Literature - 2000-2020. [Case Reports]
    J Microsc Ultrastruct. 2022 Oct-Dec; 10(4):214-218.Garg N, Diwaker P, … Sharma S
  • Amyloidosis is a complex multisystem disorder characterized by deposition of an aberrant protein in tissues and results in disruption of the normal organ function. Localized amyloidosis is a rare disorder. It commonly affects the head-and-neck region, and only 4% of these lesions are encountered in the orbital region. Hence, conjunctival amyloidosis is a very rare entity. It is thought to be a ma…
  • A Comprehensive Multidisciplinary Diagnostic Algorithm for the Early and Efficient Detection of Amyloidosis. [Journal Article]
    Clin Lymphoma Myeloma Leuk. 2022 Dec 24 [Online ahead of print]Jimenez-Zepeda V, Bril V, … Davis MK
  • Amyloidosis is a rare protein misfolding disease caused by the accumulation of amyloid fibrils in various tissues and organs. There are different subtypes of amyloidosis, with light chain (AL) amyloidosis being the most common. Amyloidosis is notoriously difficult to diagnose because it is clinically heterogeneous, no single test is diagnostic for the disease, and diagnosis typically involves mul…
  • Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. [Journal Article]
    J Natl Compr Canc Netw. 2023 01; 21(1):67-81.Kumar SK, Callander NS, … Kumar R
  • Primary systemic light chain amyloidosis (SLCA) is characterized by production of light chains that get converted to amyloid fibrils with an affinity for visceral organs and causing organ dysfunction. The therapy for SLCA is directed to recovering the function of the affected organs by targeting the abnormal plasma cell clone and slowing deposition of amyloid fibrils. The NCCN Guidelines for SLCA…
  • Amyloidosis Cutis Dyschromica in a 16-Year-Old Filipino Girl: A Case Report. [Case Reports]
    Dermatopathology (Basel). 2022 Dec 29; 10(1):20-24.Bautista FER, Marte-Jimenez MMS, Jamora MJJ
  • Amyloidosis cutis dyschromica is a rare variant of primary cutaneous amyloidosis characterized by hyper- and hypopigmented macules. In this paper, we reported a case of a 16-year-old Filipino girl with hyper- and hypopigmented to depigmented macules on the upper and lower extremities, which started when she was 9 years of age.
  • Excitation-inhibition imbalance disrupts visual familiarity in amyloid and non-pathology conditions. [Journal Article]
    Cell Rep. 2023 Jan 31; 42(1):111946.Niraula S, Doderer JJ, … Subramanian J
  • Neuronal hyperactivity induces memory deficits in Alzheimer's disease. However, how hyperactivity disrupts memory is unclear. Using in vivo synaptic imaging in the mouse visual cortex, we show that structural excitatory-inhibitory synapse imbalance in the apical dendrites favors hyperactivity in early amyloidosis. Consistent with this, natural images elicit neuronal hyperactivity in these mice. C…
  • Do Not Ignore Those Raccoon Eyes; They May Indicate Lethal AL Amyloidosis. [Case Reports]
    Case Rep Oncol. 2022 Sep-Dec; 15(3):1039-1048.Sapkota S, Kuehl S, Pulluri B
  • Light chain (AL) amyloidosis is a lethal form of systemic amyloidosis that arises from the clonal expansion of CD38+ plasma cells. Organ damage occurs when these plasma cells produce misfolded immunoglobulin light chains, which form amyloid fibrils and deposit in tissues. A minority of patients with AL amyloidosis show "raccoon eyes" caused by increased vascular fragility from accumulation of amy…
  • Individualized Approach to Management of Light Chain Amyloidosis. [Review]
    J Natl Compr Canc Netw. 2023 Jan; 21(1):91-98.Palladini G, Milani P
  • Systemic light chain (AL) amyloidosis is caused by a B-cell (most commonly plasma cell) clone that produces a toxic light chain that forms amyloid fibrils in tissues and causes severe, progressive organ dysfunction. The clinical presentation is protean, and patients are usually extremely frail, thus requiring careful adaptation of the treatment approach. However, the severity of organ involvement…
  • Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment. [Review]
    J Natl Compr Canc Netw. 2023 Jan; 21(1):83-90.Zanwar S, Gertz MA, Muchtar E
  • Immunoglobulin light chain (AL) amyloidosis is a clonal plasma cell disorder with multiple clinical presentations. The diagnosis of AL amyloidosis requires a high index of suspicion, making a delay in diagnosis common, which contributes to the high early mortality seen in this disease. Establishing the diagnosis of AL amyloidosis requires the demonstration of tissue deposition of amyloid fibrils.…
  • Bladder triangle amyloidosis: A case report and literature review. [Case Reports]
    Medicine (Baltimore). 2022 Dec 09; 101(49):e32179.Yu ZY, Yan L, … Chen B
  • CONCLUSIONS: The clinical manifestations of bladder amyloidosis are nonspecific, and under cystoscopy can be easily confused with bladder tumors. Accurate diagnosis of bladder amyloidosis relies on histopathology. Transurethral resection of bladder tumors or partial cystectomy is an option for surgical treatment; the latter should be performed if the ureteral opening is involved.
  • Monoclonal Gammopathy of Undetermined Significance in Patients With Transthyretin Amyloidosis (ATTR): Analysis Using the iStopMM Criteria. [Journal Article]
    Clin Lymphoma Myeloma Leuk. 2022 Dec 24 [Online ahead of print]Lewis E, Lee H, … Jimenez-Zepeda VH
  • CONCLUSIONS: We noted higher rates of MGUS, particularly LC-MGUS, among ATTR patients when compared to our MGUS only cohort. The high prevalence remained after utilizing the iStopMM sFLC corrected for eGFR reference ranges. Additionally, 6 ATTR patients with renal-dysfunction would have met MGUS criteria if not evaluated using the iStopMM revised measures. These findings emphasize careful interpretation of sFLC abnormalities and encourage providers to keep ATTR on the differential when work-up uncovers sFLC aberrations.
  • Clinical profile of patients with cardiac amyloidosis in India. [Journal Article]
    Indian Heart J. 2022 Dec 23 [Online ahead of print]Mohan B, Singh S, … Wander GS
  • Limited data exists on patients with cardiac amyloidosis (CA) in India, due to underdiagnosis and late presentation. We present single centre data from 13 patients over a 4 year period with a median age of 65 years. A majority presented with symptomatic heart failure (69%) and eight patients had confirmed AL amyloidosis. At the end of the follow up period, 46% patients died, with 30% of the overa…
  • Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy. [Review]
    Int J Mol Sci. 2022 Dec 18; 23(24)Nuvolone M, Girelli M, Merlini G
  • The care of systemic amyloidosis has improved dramatically due to improved awareness, accurate diagnostic tools, the development of powerful prognostic and companion biomarkers, and a continuous flow of innovative drugs, which translated into the blooming of phase 2/3 interventional studies for light chain (AL) and transthyretin (ATTR) amyloidosis. The unprecedented availability of effective drug…
  • Current Understanding of Systemic Amyloidosis and Underlying Disease Mechanisms. [Journal Article]
    Am J Cardiol. 2022 12; 185 Suppl 1:S2-S10.Picken MM
  • Amyloidosis is a group of diverse disorders caused by misfolded proteins that aggregate into insoluble fibrils and ultimately cause organ damage. In medical practice, amyloidosis classification is based on the amyloid precursor protein type, of which amyloid immunoglobulin light chain, amyloid transthyretin, amyloid leukocyte chemotactic factor 2, and amyloid derived from serum amyloid A protein …
New Search Next